Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Choice of injectable opioid treatment may help former inmates stay on track

NCT ID NCT06880718

Disease control Sponsor: Lifespan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot trial tests two long-acting injectable buprenorphine medications (Sublocade and Brixadi) in 60 incarcerated individuals with opioid use disorder who are about to be released from prison. Participants either choose their preferred medication or are randomly assigned one. The study tracks how well they stay in treatment, their opioid use, and their satisfaction over six months after release. The goal is to see if giving people a choice improves treatment retention and outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Buprenorphine (extended-release injectable formulations: Sublocade and Brixadi)
What this could lead to
If this trial succeeds, it could show that giving people leaving prison a choice of injectable buprenorphine helps them stay in treatment longer and reduces opioid relapse after release.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply to everyone. It compares two similar drugs, so differences may be small, and long-term effects are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. be at least 18 years of age and incarcerated in the RIDOC facility, 2. be currently diagnosed with OUD and enrolled in the RIDOC MOUD program, 3. have an expected release date within 120 days of study enrollment, 4. have an interest in XR-B and 5. be English speaking Exclusion Criteria: 1. individuals who are pregnant or planning conception, 2. diagnosed with a severe or acute medical or psychiatric disability preventing safe study participation or making follow-up unlikely, 3. have a release date within 21 days of initiation, or 4. have previously had an allergy to buprenorphine. Post-enrollment exclusion will include individuals if there is a change in release date beyond the 120 days and therefore no longer meet original inclusion criteria. These individuals would return to usual MOUD care.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Buprenorphine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Buprenorphine Incarceration Medications for opioid use disorder Opioid-use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rhode Island Department of Corrections

    RECRUITING

    Cranston, Rhode Island, 02920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.